IMAB

Q: What is the price of I-Mab (IMAB) today?

The current price of I-Mab (IMAB) is $ 0.00, representing a 0% gain over the past year. The stock began the year trading around $ 3.98 and is currently priced at $ 0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does I-Mab (IMAB) pay dividends?

I-Mab (IMAB) did not pay dividends over the past year.

Q: Is I-Mab (IMAB) a good investment?

I-Mab (IMAB) is currently trading at $ 0.00 with a P/E ratio of -9.06. This represents a -261% premium compared to its historical average P/E. Over the past year, the stock has gained 0 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

I-Mab

Price

$ -

return (12m)

0.00%

p/e

-9.06

p/bv

1.76

DIVIDEND YIELD

0.00%

IMAB price

IMAB

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment IMAB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals IMAB

review the fundamentals of I-Mab shares

P/E

-9.06

Sector: -3.71 Industry: -3.71

P/S (PSR)

Sector: -4.14 Industry: -4.14

P/BV

1.76

Sector: 1.95 Industry: 1.95

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

-18.48%

Sector: -63.73% Industry: -63.73%

ROE

-19.42%

Sector: -64.07% Industry: -64.07%

ROIC

-74.43%

Sector: -2,605.25% Industry: -2,605.25%

NET MARGIN

0.00%

Sector: -39.40% Industry: -39.40%

GROSS MARGIN

0.00%

Sector: 37.14% Industry: 37.14%

OPERATING MARGIN

0.00%

Sector: -38.64% Industry: -38.64%

EV/EBITDA

-9.38

Sector: -3.81 Industry: -3.81

EV/EBIT

-9.38

Sector: -3.88 Industry: -3.88

PRICE-TO-ASSETS

1.67

Sector: 1.42 Industry: 1.42

BVPS

2.40

Sector: 1.96 Industry: 1.96

EPS

-0.47

Sector: -2.09 Industry: -2.09

EQUITY-TO-ASSETS RATIO

0.95

Sector: 0.43 Industry: 0.43

LIABILITIES / ASSETS

0.05

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

0.00%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

Fundamentals IMAB

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	26.06	6.75	25.92%	2.28%	$ 548.24 B	21.83%
PFE	18.93	1.57	8.29%	6.90%	$ 141.82 B	11.83%
ABBV	101.97	-56.06	-54.98%	3.22%	$ 370.66 B	5.79%
NVO	10.37	6.26	60.40%	4.21%	$ 196.74 B	37.15%
MRK	31.14	6.06	19.45%	2.95%	$ 278.25 B	13.59%
AZN	27.42	6.01	21.93%	1.74%	$ 284.89 B	17.19%
GILD	17.36	6.83	39.33%	2.48%	$ 160.03 B	30.99%
BMY	16.05	5.81	36.19%	4.36%	$ 116.80 B	15.01%
ZTS	12.41	10.14	81.75%	2.61%	$ 32.80 B	27.79%
REGN	14.80	2.08	14.08%	0.57%	$ 65.49 B	29.65%
HALO	22.81	36.23	158.82%	0.00%	$ 7.96 B	23.13%
AMGN	22.29	18.92	84.87%	3.00%	$ 173.86 B	20.96%
MCK	19.86	-113.39	-570.98%	0.41%	$ 94.57 B	1.18%
HRMY	11.88	1.90	16.00%	0.00%	$ 1.73 B	16.20%
VRTX	25.56	5.73	22.41%	0.00%	$ 110.89 B	35.51%
CAH	30.11	-17.52	-58.20%	1.03%	$ 46.82 B	0.62%
ADMA	11.96	5.07	42.37%	0.00%	$ 1.98 B	32.43%
BIIB	20.56	1.51	7.36%	0.00%	$ 28.21 B	13.81%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*The value considers the reinvestment of dividends.

IMAB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT I-Mab

I-Mab

Average Investor10 user rating

4.0 (5 people)

United States

10 years

Founded: 2016

2020

Time since IPO - 6 years

228

Employees

I-Mab (United States) is listed on the Nasdaq and has a market capitalization of $346.04 Millions, with shareholders equity totaling $196.73 Millions.

The company employs approximately 228 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, I-Mab reported $- in revenue, generating net income of $-38.20 Millions.

Key financial metrics include a P/E ratio of -9.06, a price-to-book (P/B) ratio of 1.76, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker IMAB.

Market cap

$ 346.04 Millions

Net worth

$ 196.73 Millions

$ 196,730,000.00

Assets

$ 206.71 Millions

$ 206,710,000.00

Total Shares Outstanding

82.00 Millions

82,000,000

Average Daily Trading Volume

$ 638.30 Thousand

$ 638,295.66

Sector

Health Care

Industry

Biotechnology

IMAB

IMAB revenue and profits

Financial Results IMAB

DRAG THE FRAME TO SEE MORE DATA

IMAB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 766.08 7,52% (12M)

P/E

19.86

0.41%

ROE

-570.98%

P/BV

-113.39

CAH - Cardinal Health

$ 200.68 33,22% (12M)

P/E

30.11

1.03%

ROE

-58.20%

P/BV

-17.52

JNJ - Johnson & Johnson

$ 234.34 58,44% (12M)

P/E

26.06

2.28%

ROE

25.92%

P/BV

6.75

MRK - Merck & Co.

$ 122.41 63,49% (12M)

P/E

31.14

2.95%

ROE

19.45%

P/BV

6.06

AZN - AstraZeneca

$ 187.03 34,10% (12M)

P/E

27.42

1.74%

ROE

21.93%

P/BV

6.01

ABBV - AbbVie

$ 215.70 21,44% (12M)

P/E

101.97

3.22%

ROE

-54.98%

P/BV

-56.06

NVO - Novo Nordisk

$ 44.96 --30,01% (12M)

P/E

10.37

4.21%

ROE

60.40%

P/BV

6.26

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 766.08 7,52% (12 M)

P/L

19.86

0.41%

ROE

-570.98%

P/VP

-113.39

CAH - Cardinal Health

$ 200.68 33,22% (12 M)

P/L

30.11

1.03%

ROE

-58.20%

P/VP

-17.52

JNJ - Johnson & Johnson

$ 234.34 58,44% (12 M)

P/L

26.06

2.28%

ROE

25.92%

P/VP

6.75

MRK - Merck & Co.

$ 122.41 63,49% (12 M)

P/L

31.14

2.95%

ROE

19.45%

P/VP

6.06

AZN - AstraZeneca

$ 187.03 34,10% (12 M)

P/L

27.42

1.74%

ROE

21.93%

P/VP

6.01

ABBV - AbbVie

$ 215.70 21,44% (12 M)

P/L

101.97

3.22%

ROE

-54.98%

P/VP

-56.06

NVO - Novo Nordisk

$ 44.96 --30,01% (12 M)

P/L

10.37

4.21%

ROE

60.40%

P/VP

6.26

Frequently Asked Questions

What is the price of I-Mab (IMAB) today?

The current price of I-Mab (IMAB) is $ 0.00, representing a 0% gain over the past year. The stock began the year trading around $ 3.98 and is currently priced at $ 0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does I-Mab (IMAB) pay dividends?

I-Mab (IMAB) did not pay dividends over the past year.

Is I-Mab (IMAB) a good investment?

I-Mab (IMAB) is currently trading at $ 0.00 with a P/E ratio of -9.06. This represents a -261% premium compared to its historical average P/E. Over the past year, the stock has gained 0 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy I-Mab (IMAB) stock?

You can buy I-Mab (IMAB) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol IMAB and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of I-Mab (IMAB) yield today?

Over the past month, I-Mab (IMAB) has returned 0.00% — 0.00% over the past year, and 0.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of I-Mab (IMAB) today at the current price of $ 0.00 your total investment would be $ 0.00.

Based on historical performance, the investment would have grown to approximately:

$ 0.00 after 1 year
$ 0.00 after 5 years
$ 0.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

IMAB

I-Mab

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment IMAB

review the fundamentals of I-Mab shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

current DY: 0.00%

5-year average DY: 0.00%

ABOUT I-Mab

I-Mab

United States

10 years

2020

228

PROFIT X PRICE IMAB

Financial Results IMAB

IMAB cash flow

Asset, Revenue and Profit Growth - IMAB

IMAB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

Frequently Asked Questions